Last updated on May 2020

A Study of XmAb 23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)


Brief description of study

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 in subjects with selected advanced solid tumors.

Clinical Study Identifier: NCT03752398

Find a site near you

Start Over

Florida Cancer Specialists

Sarasota, FL United States
5.43miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.